KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity: 2014-2025

Historic Liabilities and Shareholders Equity for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $527.5 million.

  • Aurinia Pharmaceuticals' Liabilities and Shareholders Equity fell 3.97% to $527.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 2.43%. This contributed to the annual value of $550.6 million for FY2024, which is 0.47% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $527.5 million for Q3 2025, which was up 4.97% from $502.6 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $555.0 million during Q3 2023, with a 5-year trough of $360.1 million in Q3 2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $527.5 million in 2025 and averaged $525.3 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity dropped by 22.02% in 2021 and then surged by 35.61% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $543.4 million in 2021, then dropped by 13.34% to $470.9 million in 2022, then rose by 16.40% to $548.1 million in 2023, then rose by 0.47% to $550.6 million in 2024, then declined by 3.97% to $527.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $527.5 million for Q3 2025, versus $502.6 million for Q2 2025 and $504.9 million for Q1 2025.